Morphologic and cytochemical observations on the overt leukemic phase of therapy-related leukemia.
Morphologic and cytochemical observations on the overt leukemic phase of therapy-related leukemia.
复制标题
对治疗相关白血病的明显白血病阶段的形态学和细胞化学观察。
DOI：
10.1093/ajcp/79.5.525
复制
发表时间：
1983
影响因子：
3.5
通讯作者：
J. Rowley
中科院分区：
文献类型：
--
作者：
J. Vardiman;A. Coelho;H. Golomb;J. Rowley
临床急性非淋巴细胞白血病原发恶性肿瘤(2度)治疗后白血病细胞的形态和细胞化学特征与初发急性非淋巴细胞白血病患者相比有几点不同。2度ANLL患者细胞内未见Auer棒，而初发ANLL患者中54例(42%)可见Auer棒。根据FAB标准，21例2度ANLL患者中只有1例(4.7%)被归类为M-4，相比之下，129例初发ANLL患者中46例(36%)被归类为M-4。在10例2度ANLL患者中，仅1例(10%)有超过10%的过氧化物酶阳性白血病细胞，而在20例类似FAB亚型的ANLL患者的对照组中，有19例(95%)有超过10%的阳性细胞。11例(18%)2度ANLL患者中有2例(18%)有10%或以上的萘酚AS-D氯乙酸酯酶阳性细胞，而19例初发ANLL患者中有9例(47%)呈阳性细胞。非特异性酯酶活性在10例2度ANLL患者中只有1例(10%)存在于10%或更多的细胞中，而在20例对照组中只有7例(35%)存在非特异性酯酶活性。以前的报道表明，2度非淋巴细胞白血病患者的细胞遗传学异常和治疗反应与初治非淋巴细胞白血病患者不同；我们的研究结果表明，在形态和细胞化学方面也存在差异。
Comparison of morphologic and cytochemical features of the leukemic cells of patients with overt acute nonlymphocytic leukemia following therapy for primary malignancies (2 degrees-ANLL) to those of patients with ANLL de novo revealed several differences. No Auer rods were seen in cells of patients with 2 degrees-ANLL, but they were seen in 54 (42%) of 129 cases of ANLL de novo. Only one (4.7%) of 21 patients with 2 degrees-ANLL was classified as M-4 by FAB criteria, compared to 46 (36%) of 129 patients with ANLL de novo classified as M-4. Only one (10%) of 10 patients with 2 degrees-ANLL had more than 10% peroxidase-positive leukemic cells, whereas 19 (95%) of 20 of a control group of patients with ANLL de novo of similar FAB subtypes had more than 10% positive cells. Two of 11 (18%) 2 degrees-ANLL patients had 10% or more naphthol-AS-D chloroacetate esterase-positive cells, in contrast to nine (47%) of 19 patients with ANLL de novo. Nonspecific esterase activity was present in 10% or more of cells in only one (10%) of 10 patients with 2 degrees-ANLL studied, as compared to seven (35%) of 20 of the control group. Previous reports indicate that patients with 2 degrees-ANLL have cytogenetic abnormalities and therapeutic responses that differ from those in ANLL de novo; our findings indicate that there are morphologic and cytochemical differences as well.